3‐Aryl Coumarin Derivatives Bearing Aminoalkoxy Moiety as Multi‐Target‐Directed Ligands against Alzheimer's Disease

2019 ◽  
Vol 16 (5) ◽  
pp. e1800436
Author(s):  
Helia Abdshahzadeh ◽  
Mostafa Golshani ◽  
Hamid Nadri ◽  
Iraj Saberi Kia ◽  
Zahra Abdolahi ◽  
...  
2008 ◽  
Vol 63 (5-6) ◽  
pp. 366-370 ◽  
Author(s):  
Ilkay Orhan ◽  
Fatma Tosun ◽  
Bilge Şener

Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are the key enzymes in pathogenesis of Alzheimer’s disease (AD), which is characterized by a deficit in central cholinergic transmission. In the current study, AChE and BChE inhibitory activities of seven coumarin derivatives [umbelliferone (1), 4-methylumbelliferone (2), 4-hydroxycoumarin (3), scopoletin (4), 8-methoxypsoralen (5), bergapten (6), and iso-bergapten (7)], a furanocoumarin mixture obtained from Heracleum crenatifolium Boiss. (Umbelliferae), as well as of two anthroquinone derivatives [rhein (8) and aloe-emodine (9)] and one stilbene, rhapontin (10), were tested by the spectrophotometric method of Ellman using an ELISA microplate-reader at 1 mg mL-1. Among them, the furanocoumarin mixture [(68.8 ± 0.76)%], bergapten [(62.4 ± 0.74)%], aloe-emodine [(57.2 ± 1.32)%], scopoletin [(53.1 ± 0.83)%], and 4-methylumbelliferone [(62.3 ± 1.03)%] showed over 50% inhibition against AchE, while umbelliferone [(54.3 ± 0.23)%], 4-methylumbelliferone [(80.9 ± 1.17)%], scopoletin [(73.5 ± 1.01)%], 8-methoxypsoralen [(67.1 ± 0.98)%], as well as the furanocoumarin mixture [(76.7 ± 0.95)%] had a notable anti-BChE effect.


2021 ◽  
Vol 36 (1) ◽  
pp. 1607-1621
Author(s):  
Sheunopa C. Mzezewa ◽  
Sylvester I. Omoruyi ◽  
Luke S. Zondagh ◽  
Sarel F. Malan ◽  
Okobi E. Ekpo ◽  
...  

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Siju Ellickal Narayanan ◽  
Hariraj Narayanan ◽  
Minil Mukundan ◽  
Saranya Balan ◽  
C. P. Vishnupriya ◽  
...  

Abstract Background The study aimed to design, synthesize and evaluate various brominated derivatives of 7-hydroxy coumarin as a new scaffold against Alzheimer’s disease by in vivo and in vitro models. A group of three novel pyrazoles endowed with brominated 7-hydroxy 4-methyl coumarin derivatives were designed. Among the designed compounds, a single entity (D1) was selected based on the docking score, which could be considered mainly for the treatment of Alzheimer’s disease. Three novel pyrazoles endowed with brominated 7-hydroxy 4-methyl coumarin derivatives were designed and docking studies of these compounds were carried out using Argus lab4.0.1 version. According to the docking score, a single entity of compound (D1) was selected for further study. The structure of the compound (D1) was explored by spectral analysis. The anti-Alzheimer’s activity was evaluated by in vivo and in vitro methods. All results were compared statistically by one-way ANOVA using GraphPad Prism. Results Molecular docking studies revealed that the compound D1 was able to bind simultaneously to the amino acid and in the active sites of the acetylcholine esterase enzyme. In acetylcholine esterase inhibition assay, the compound shows a significant increase in acetylcholine esterase level. The MAO inhibitory activities were in the nanomole range (human MAO-A IC50 = 3.9, human MAO-B IC 50 = 4.4). DPPH (2,2-diphenyl-1-picryl-hydrazyl-hydrate) assay showed that the compound shows a promising antioxidant property. In the evaluation of learning and memory of compound D1 using elevated plus maze, the compound D1-pretreated group showed a significant increase in memory and learning when compared with donepezil. Conclusions Among the designed series of pyrazole endowed with brominated 7-hydroxyl 4-methyl coumarin derivatives, compound D1 showed good antioxidant property and acetylcholine esterase and MAO inhibitory activity; based on this property, the synthesized compound D1 can be considered a new scaffold on Alzheimer’s disease.


2019 ◽  
Vol 42 ◽  
Author(s):  
Colleen M. Kelley ◽  
Larry L. Jacoby

Abstract Cognitive control constrains retrieval processing and so restricts what comes to mind as input to the attribution system. We review evidence that older adults, patients with Alzheimer's disease, and people with traumatic brain injury exert less cognitive control during retrieval, and so are susceptible to memory misattributions in the form of dramatic levels of false remembering.


Sign in / Sign up

Export Citation Format

Share Document